MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Cilostazol

CAS No. : 73963-72-1

MCE 国际站：Cilostazol

产品活性：Cilostazol (OPC 13013) 是有效、选择性的心血管系统中磷酸二酯酶 3 亚型 PDE 3A 的抑制剂，IC₅₀ 值为 0.2 μM。

研究领域：Metabolic Enzyme/Protease  |  Autophagy

作用靶点：Phosphodiesterase (PDE)  |  Autophagy

In Vitro: Cilostazol selectively inhibits cGMP-inhibited phosphodiesterase (PDE 3) and is a potent inhibitor of platelet aggregation induced by various agonists.
Cilostazol inhibits stress-induced human platelet aggregation (SIPA) dose-dependently, with an IC₅₀ of 15 μM for SIPA, and with a similar IC₅₀ of 12.5 μM for ADP-induced platelet aggregation.
Cilostazol directly and effectively inhibits the activation of HSC but not of Kupffer cells.

In Vivo: Cilostazol (clinically used doses; p.o.; for 2 weeks) could alleviate CCl4 -induced hepatic fibrogenesis in vivo, presumably due to its direct effect to suppress HSC activation.
Cilostazol (intraperitoneal injection; 10 mg/kg; 7 consecutive days after ischemia) attenuates neurological dysfunctions, brain atrophy and infarct volume, and inhibits astrocyte proliferation/glial scar formation and accelerated the angiogenesis in the ischemic boundary zone 7 and 28 days after ischemia.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Metabolism/Protease Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Autophagy Compound Library  |  Drug Repurposing Compound Library  |  Anti-Cardiovascular Disease Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Alzheimer's Disease Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Neurodegenerative Disease-related Compound Library  |  Rare Diseases Drug Library  |  Anti-Colorectal Cancer Compound Library   |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Off-patent Drug Library  |  Highly Selective Inhibitors Library  |  Highly Selective Activators Library  |  Cirsimarin  |  PDE11-IN-1  |  Enpp-1-IN-2  |  PAT-347  |  Vardenafil-d₅  |  Bay 60-7550  |  Deltarasin hydrochloride  |  HA155  |  Apremilast  |  Enpp-1-IN-6  |  Roflumilast  |  RS-25344 hydrochloride  |  PDE4-IN-6  |  Sp-cAMPS  |  ITI-214  |  Irsenontrine maleate  |  Lodenafil  |  Osoresnontrine  |  Deltasonamide 2  |  PF-07038124  |  Ziritaxestat  |  ATX inhibitor 22  |  Milrinone-d₃  |  Avanafil-¹³C,d₃  |  MT-3014  |  ATX inhibitor 19  |  Homo Sildenafil-d₅  |  Furamidine  |  PDE4-IN-12  |  Enpp-1-IN-8

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。